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1. INTRODUCTION
The phospholipase C (PLC) isozymes catalyze conversion of phosphatidylinositol 4,5-
bisphosphate (PtdIns(4,5)P2) into the Ca2+-mobilizing second messenger inositol 1,4,5-
trisphosphate (inositol (1,4,5)P3) and the protein kinase-activating second messenger
diacylglycerol (DAG).1 Many PLC-dependent cellular responses occur in addition to those
mediated by these classical second messengers since the activities of a broad range of
membrane, cytosolic, and cytoskeletal proteins are regulated by PtdIns(4,5)P2 binding.2–4
Mammals express 13 different PLCs (Figure 1), which differ markedly in their modes of
upstream regulation and physiological functions.5 Many growth factors, antigens, and other
extracellular stimuli signal through tyrosine phosphorylation of the PLC-γ isozymes,
whereas an even larger group of hormones, neurotransmitters, chemoattractant and
chemosensory molecules, and other extracellular stimuli promote physiological effects
through heterotrimeric G protein-dependent activation of the PLC-β isozymes. These and
other forms of receptor-promoted signaling pathways also communicate to Ras superfamily
GTPases, which in turn directly activate certain PLC isoyzmes. Thus, PLC-dependent signal
transduction provides one of the major fabrics for communication of cells, and delineation
of its function at all levels from the intact animal to the atomic resolution of mechanism is
fundamental to understanding mammalian biology.
Many excellent reviews on PLC-dependent signaling are available that focus, for example,
on early aspects of the discovery and function of receptor-promoted formation of
Ins(1,4,5)P3/diacylglycerol and mobilization of Ca2+,1,6,7 classification and regulation of the
PLC isozymes,8–10 tyrosine phosphorylation-dependent activation,11,12 activation through
Ras superfamily GTPases,5,13,14 physiology,15,16 and structure/function.17–19 We have
limited this review to a general introduction of the domain and structural features of the PLC
isozymes and then consider in detail recent advances made in understanding the mechanisms
through which Gα-subunits of the Gq family bind to and activate PLC-β isozymes and how
the PLC-β isozymes in turn promote inactivation of this signaling complex by stimulating
GTP hydrolysis by the GTP-activated G protein.
2. CANONICAL STRUCTURE OF PLC ISOZYMES
The thirteen mammalian PLC isozymes (Figure 1) comprise six different subfamilies.5,9
Each of these isozymes contains a common catalytic core that includes an N-terminal
pleckstrin homology (PH) domain (this is not present in PLC-ζ), an array of four EF-hands,
a catalytic triose phosphate isomerase (TIM) barrel comprised of X and Y subdomains, and
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a C-terminal C2 domain. The three-dimensional structure of PLC-β3,20 shown in Figure 2 in
an activated complex with Gαq, illustrates the conserved core structure found in all PLC
isozymes.
The PH domain of PLC-δ1 binds PtdIns(4,5)P2 with high affinity, and a three-dimensional
crystal structure of this archetypal PH domain revealed a sandwich of seven β-strands
capped by an α-helix at the C-terminus.21 Although PH domains are structurally conserved,
they mediate diverse functions. The PH domain of PLC-δ1 is tethered to the core catalytic
domain through a flexible linker and is likely to be mobile.21–23 PtdIns- (4,5)P2 binding to
the PH domain anchors PLC-δ1 at the plasma membrane, and multiple PtdIns(4,5)P2
molecules are subsequently hydrolyzed by the catalytic site in a process sometimes referred
to as membrane scooting. In contrast, the PH domains of PLC-β isozymes, which lack the
basic residues necessary for PtdIns(4,5)P2 binding, are tightly associated with the other
domains of the catalytic core.24 Although PH domain binding of PtdIns(4,5)P2 or other
phosphoinositides is not important for regulation of PLC-βs, PLC-β2 is activated by high-
affinity binding of Rac GTPases to this domain.24–26
EF-hands consist of two helices joined by a loop.27 Although EF-hands are known to be
calcium-binding motifs, the three-dimensional structures of PLC isozymes illustrate a
relatively high degree of flexibility in these domains, and little evidence for Ca2+ binding in
these regions is available.22,24 However, a cassette between the third and fourth EF-hands of
PLC-β isozymes plays an indispensible role in PLC-β-mediated stimulation of GTP
hydrolysis by Gαq.20 Structure/function aspects of this signaling motif are discussed in
detail below.
C2 domains are composed of an eight-β-stranded antiparallel sandwich, with three loops at
one end of the sandwich typically forming calcium-binding sites.28 The C2 domain of PLC-
δ1 binds Ca2+ and has been proposed to promote translocation to the plasma membrane.29
However, the residues that mediate Ca2+ binding are not generally conserved in other PLC
isozymes, and little evidence of C2 domain-dependent regulation by Ca2+ exists for most
PLC isozymes. The major binding determinants for activated Gαq are found just outside the
N- and C-terminal ends of the C2 domain of PLC-β isozymes.20 Molecular aspects of this
signaling surface are considered below.
The catalytic TIM barrel is the most highly conserved (60–70% identical) component of the
13 PLC isozymes, and the X and Y subdomains of this region fold to form the lipase active
site.22,30 Residues that bind the 4′- and 5′-phosphorylated hydroxyl groups of the inositol
ring of PtdIns(4,5)P2 are invariantly conserved in all PLC isozymes.22,31 Similarly
conserved residues coordinate an essential Ca2+ cofactor. A conserved glutamine acts as a
putative general base for deprotonation of the 2-hydroxyl group of the inositol group, and
nucleophilic attack of the 2-hydroxyl group on the 1-phosphate, facilitated by the catalytic
Ca2+, produces a cyclic intermediate.32,33 In the second step of the lipase reaction, a
conserved histidine uses a proton from water to promote nucleophilic attack on the
pentavalent cyclic intermediate, and diacylglycerol and Ins(1,4,5)P3 are formed.22,31,32,34
Not only are all residues participating in the catalytic reaction conserved in all PLCs, but
they are also positioned similarly in X-ray crystal structures solved of PLC- δ1,22 PLC-β2,24
and PLC-β3.20
The core catalytic domain is essentially conserved in all PLC isozymes, but the six different
subclasses of PLCs contain additional structural domains that mediate different forms of
upstream and, at least in one case, downstream regulation (Figure 1). Most of the remainder
of this review focuses on the structure of PLC-β isozymes and the function of these
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isozymes in signaling complexes with Gαq. The structure/function of the other subclasses of
PLC isozymes is briefly summarized.
The two PLC-γ isozymes PLC-γ1 and PLC-γ2 provide major cell signaling responses
downstream of receptor and nonreceptor tyrosine kinases.9,11 These isozymes uniquely
contain conserved domains that “split” the X and Y subdomains of the TIM barrel. These
include a second PH domain, two Src-homology 2 (SH2) domains, and an Src-homology 3
(SH3) domain. Activation of the two PLC-γ isozymes involves tyrosine phosphorylation-
dependent binding of receptor and nonreceptor tyrosine kinases to the N-terminal SH2
domain of PLC-γ and subsequent tyrosine kinase-stimulated phosphorylation of a tyrosine
residue- (s) in the region between the C-terminal SH2 domain and SH3 domain.9,11,35 This
phosphotyrosine in turn interacts with the C-terminal SH2 domain to promote activation (see
the discussion of activation below). Interestingly, PLC-γ2 also is activated by binding of the
small GTPase Rac to the split PH domain found in the linker region between the X and Y
subdomains.36,37
PLC-ε was discovered as a Ras-binding protein and contains two conserved Ras-associating
domains at its C-terminus.38–41 H-Ras, K-Ras, Rap1A, Rap2A, and Rap2B have been
reported to bind to the second Ras-association (RA) domain of this isozyme and to stimulate
its lipase activity.39,42 A Cdc25 guanine nucleotide exchange domain (GEF) is present in the
N-terminal region of PLC-ε. Although the selectivity and molecular details of this GEF
function have not been completely defined, PLC-ε is an upstream activator of Ras- and Rap-
dependent signaling43,44 and also apparently exhibits a feed-forward form of self-regulation,
which may be important in, for example, localizing PLC-ε to different membrane
compartments in the cell.
PLC-ζ is a sperm-specific signaling protein that plays an indispensible role in the acrosome
reaction.45 This PLC lacks a PH domain and is uniquely sensitive to activation by Ca2+,
although the molecular details of this process remain undefined. The two PLC-η isozymes
PLC-η1 and PLC-η2 are recently discovered PLCs that have a long C-terminal domain.46–48
These isozymes are prominently expressed in neurons as well as in astrocytes, and PLC-η2
is directly activated by Gβγ-subunits of heterotrimeric G proteins.49
3. PLC-β-DEPENDENT REGULATION OF INOSITOL LIPID SIGNALING BY G
PROTEIN-COUPLED RECEPTORS
Heterotrimeric G proteins, consisting of a guanine nucleotide- binding Gα-subunit and an
obligate dimer of a Gβ- and a Gγ-subunit, were first discovered as components of hormone-
receptor- regulated adenylyl cyclase and of the rhodopsin-promoted phototransduction
cascade.50 Agonist-occupied G protein- coupled receptors (GPCRs) promote exchange of
GTP for GDP on Gα-subunits, which bind and activate downstream effectors. Later work
revealed that Gβγ-subunits released from activated heterotrimeric G proteins also bind to
and activate downstream effectors.51,52
The obligatory involvement of PLC linking activation of many neurotransmitter and
hormone receptors in mobilization of intracellular Ca2+ and activation of protein kinase C
was elucidated in the work of Michell, Berridge, Nishizuka, and others in the 1970s and
early 1980s.1,6,7 Indirect studies suggested involvement of a G protein in activation of
PLC,53–56 and Litosch and Fain57 and Cockcroft and Gomperts58 first reported in 1985 the
activation of PLC by GTP in cell-free preparations. This proved to be a general phenomenon
illustrated with membranes from a variety of target tissues and with GTP-dependent
activation observed with agonists for a broad range of GPCRs.59–62 Simon and his
colleagues used degenerate primers to identify novel Gα-subunits,63,64 including the genes
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for Gα-subunits, i.e., Gαq, Gα11, Gα14, and Gα16, that comprise the Gq family of G
proteins. Smrcka et al.,65 Taylor et al.,66 and Waldo et al.67 subsequently showed in 1991
that Gα-subunits of the Gq family directly activate PLC-β isozymes. Importantly, Gαq was
shown to activate PLC-β without activating PLC-γ and PLC-δ isozymes.66 Several
excellent reviews focus on early aspects of G protein-mediated regulation of PLC-β
isozymes.68–70
GPCRs comprise up to 5% of mammalian genomes, and a large percentage of these
signaling proteins, estimated to be up to 40% of those in the brain, signal primarily through
the Gq family of Gα-subunits. The four PLC-β isozymes in turn receive their major form of
upstream regulation through activation of Gq family heterotrimeric G proteins. These
isozymes are widely, but differentially, expressed, and their broad involvement in many
physiological responses is not surprising given the number and functional variety of the
extracellular stimuli that activate Gq-coupled GPCRs.
A long (~350 residue), relatively poorly conserved, C-terminal domain has often been
considered a key structural component of the PLC-β isozymes. This view was in part driven
by observations that removal of this region led to loss of the capacity of Gαq to activate
PLC-β after transient overexpression in cells71 or in assays with partially purified proteins.72
The capacity of PLC-β isozymes to promote GTP hydrolysis also was tentatively73,74
mapped to this region. The C-terminal domain also has long stretches of polybasic residues
and has been proposed to be important for membrane association mediated by electrostatic
interactions.75 An X-ray structure of a portion of this region was solved and was shown to
take the form of a unique coiled-coil domain that was suggested to be important for
dimerization, membrane association, and interaction with Gq familyGα-subunits.76
Although most research has suggested that the long C-terminal domain serves as the
predominant Gαqinteracting region(s) of PLC-β isozymes, a recent crystal structure of an
activated complex of Gαq with PLC-β3 surprisingly indicates that the Gαq-binding
interface exists in a stretch of approximately 30 residues immediately C-terminal to the C2
domain.20 Thus, although it plays a role in activation, the function of the remainder of the C-
terminal domain remains undefined. Does its propensity to interact with membranes simply
provide a second component for membrane anchoring/active site orientation that is driven in
a functional manner by binding of activated Gαq to other regions of PLC-β?
Giershick and his colleagues first suggested that Gβγ-subunits also activate PLC,77 and
reconstitution assays with purified avian and mammalian PLC-β isozymes illustrated that
Gβγ stimulates inositol lipid signaling by directly activating these signaling proteins.78–80
PLC-β2 and PLC-β3 are more sensitive to this mode of regulation than PLC-β1 and PLC-
β4. Heterotrimeric G proteins of the Gi family often are expressed at relatively high levels,
and Gβγ-dependent activation of effectors usually occurs through activation of Gi-coupled
GPCRs. Thus, a broad range of Gi-coupled GPCRs have been reported to promote inositol
lipid signaling responses that are sensitive to inactivation by pretreatment with pertussis
toxin.52
The three-dimensional structure of a Gβγ/PLC-β signaling complex is not available.
Therefore, the Gβγ-binding surface of PLC-β2 and PLC-β3 is not unambiguously known,
although both the PH domain81 and a region of the Y domain82 in the TIM barrel have been
implicated. The reader is referred to an excellent recent review on Gβγ-mediated signaling
that details what is known about the interaction of Gβγ with PLC-β isozymes.52
4. PLC-β-PROMOTED GTP HYDROLYSIS BY Gαq
The capacity of Gα-subunits to hydrolyze GTP and therefore self-regulate their activation
state was first realized almost three decades ago.83,84 Whether this process was regulated by
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other proteins was a matter of conjecture, but observations that the rate of hydrolysis of GTP
by purified Gα-subunits was much lower than the turnoff rate of G protein-mediated
signaling responses in intact cell systems were consistent with this idea.50,85 The discovery
of GTPase-activating proteins (GAPs) for the small G protein Ras86 also added support to
the concept that downstream regulators of the activity of heterotrimeric G proteins might
exist.
Early observations on the properties of purified Gαq revealed a remarkably slow rate of
basal guanine nucleotide exchange as well as a low rate of GTP hydrolysis observed in
single turnover type assays.87 However, Bernstein and Ross and their colleagues88 reported
ground-breaking studies in 1992 that provided an initial explanation for the differences
between the rates of GTP hydrolysis by purified Gαq and the rates of turnoff of, for
example, GPCR-promotedCa2+ signaling observed in vivo. A reconstitution system was
developed in which purified M1 muscarinic cholinergic receptors were reconstituted in
model phospholipid vesicles with purified heterotrimeric Gq. Steady-state hydrolysis of
GTP was enhanced by addition of the agonist carbachol, which promoted an increase in
guanine nucleotide exchange. However, the overall rate of GTP hydrolysis remained
relatively slow due to the intrinsically low rate constant for GTP hydrolysis by Gαq.
Addition of purified PLC-β1 caused a remarkable increase in GTP hydrolysis, and the
concentration dependence for this effect was similar to the concentration dependence for
Gαq-stimulated lipase activity. Whereas PLC-β1 promoted hydrolyis of GTP by Gαq, it had
no effect on the rate of hydrolysis of GTP by Gαs or Gαo. The effect of PLC-β1 on steady-
state GTP hydrolysis did not occur due to promotion of guanine nucleotide exchange since
the rates of basal and agonist-stimulated [35S]GTPγS binding were essentially unchanged in
the presence of PLC-β1. Moreover, the rate of hydrolysis of GTP observed with [γ32P]GTP-
prelabeled Gαq was enhanced up to 50-fold by PLC-β1, illustrating that PLC-β directly
stimulates GTP hydrolysis by, and therefore inactivation of, its upstream activator.
This early work identified the first GAP for a heterotrimeric G protein and provided the
much needed explanation for differences in in vitro and in vivo turnoff reactions for
activated heterotrimeric G proteins.88 An additional important new concept was conceived
in this work. Thus, it was proposed that the GAP activity of PLC-β results in a rate of GTP
hydrolysis that is sufficiently high to prevent activated receptor from dissociating from the
Gq/PLC-β signaling complex during the lifetime of bound GTP (Figure 3). That is, PLC-β
rapidly returns the activated Gα-subunit to the GDP-bound state, the activated receptor
remains in the complex, where it promotes rapid dissociation of GDP, and the activation
cycle is reinitiated. As a consequence, agonist binding to a single receptor results in multiple
cycles of activation for the Gq/PLC-β complex. Conversely, lateral diffusion of proteins out
of the complex and loss of signal acuity inherent in the process of reengaging another Gq/
PLC-β pair are circumvented.
The subsequent work of Ross and his colleagues elegantly expanded on their initial
observation of GAP activity of PLC-β. Thus, precise regulation of signal initiation,
termination, and amplitude occurs through coordinated effects of the activated GPCR and
PLC-β on guanine nucleotide exchange and GTP hydrolysis.89 Quench flow techniques
were applied to show that PLC-β-bound Gαq hydrolyzes GTP with a t1/2 of ~25 ms at 30
°C.90 This rate is 1000-fold greater than the basal rate of GTP hydrolysis by Gαq and
clearly is consistent with a physiologically relevant inactivation rate for inositol lipid
signaling in vivo.
A kinetic model for coordinate regulation of the GPCR/Gq/PLC-β signaling node has been
described recently and tested with kinetic measurements in vitro.91 The results from these
analyses provide details on how the GAP activity of the PLC-β effector can provide rapid
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shutoff of signaling response upon termination of agonist activation while simultaneously
maintaining high signal response in the presence of an activating agonist. The model and
related kinetic data also indicate that whereas the activated GPCR stays bound to Gαq
throughout the GTPase cycle, PLC-β mainly binds during the GTP-bound state of Gαq.
5. STRUCTURAL BASIS FOR Gαq BINDING AND GAP ACTIVITY OF PLC-β
Receptor-promoted activation of Gq results in stimulation of PLC-β, and bound PLC-β
inactivates its activating Gα-subunit by enhancing the rate of GTP hydrolysis by ~1000-
fold. A snapshot of this process recently was revealed by Waldo et al.,20 who solved the
three-dimensional structure of an activated complex of Gαq/PLC-β3 (Figure 2). This
advance together with related biochemical analyses has delineated at the atomic level the
mechanisms whereby PLC-β binds to activated Gαq and increases the rate of hydrolysis of
bound GTP.
Activated Gαq interacts with three different regions of PLC-β 3. First, an approximately 30
amino acid cassette just C-terminal to the C2 domain forms a helix—turn—helix that binds
in a shallow declivity between switch 2 and the third α-helix of activated Gαq (Figures 2
and 4). This region in Gα-subunits is known to be important for the binding of effectors. For
example, cyclic GMP phosphodiesterase-γ binds activated Gαt (transducin) in a similar
manner.92 The helix—turn—helix is highly conserved in all PLC-β isozymes, including the
two found in Caenorhabditis elegans, and mutation of Gαq-interacting residues in this
region of PLC-β isozymes causes loss of the capacity to bind Gαq. Binding to activated
Gαq is supported by a second region in PLC isozymes that includes a number of charged
residues just N-terminal to the C2 domain. These residues, which form salt bridges with
complementary residues in Gαq, are largely conserved in the PLC-β isozymes, and their
mutation reduces Gαq binding. Importantly, the helix—turn—helix of PLC-β3 or the helix
—turn—helix plus the residues on the N-terminal side of the C2 domain were introduced
into PLC-δ1, which does not bind Gαq. Addition of these regions from PLC-β into PLC-δ1
resulted in chimeric forms of the isozyme that bound Gαq in an AlF4-dependent manner.
Moreover, whereas PLC-δ1 is insensitive to activation by Gαq, GTP- and agonist-
dependent increases in lipase activity were observed with the chimeras using phospholipid
vesicles reconstituted with purified heterotrimeric Gq and P2Y1 receptors.
A number of studies had suggested as discussed above that the C-terminal region of PLC-β
isozymes is important for Gαq binding as well as for the GAP activity of PLC-β against
Gαq.71–74,76 The Gαq/PLC-β3 structure provided a surprise by revealing the prominent role
of the helix—turn—helix region and sequence on the N-terminal side of the C2 domain in
mediating Gαq binding.20 Indeed, wild-type PLC-β3 and a deletionmutant of PLC-β3 that
lacked almost the entire C-terminal region bound to activated Gαq with essentially the same
affinity. Equally surprisingly, a third region in PLC-β 600 residues away in the primary
amino acid sequence from the C-terminal region interacts directly with GTP-binding
residues in Gαq (Figures 2 and 4). This eight amino acid cassette is conserved in the loop
between EF-hand 3 and EF-hand 4 in all PLC-β isozymes, including the two C. elegans
proteins, but other PLC isozymes lack this cassette. This region was disordered in the
structure of PLC-β2 alone93 as well as in the structure of PLC-β2 in the activated complex
with Rac1.24 However, it becomes ordered in the process of PLC-β binding to activated
Gαq, and examination of the interactions with Gαq mediated by residues in this region
reveals the mechanism whereby PLC-β enhances the rate of hydrolysis of GTP (Figure 4).
Thus, Asn260 is presented in a tight turn of the EF-hand 3/4 loop of PLC-β3, and the side
chain nitrogen of this residue directly interacts with the side chain carbonyl of Gln209 of
Gαq. This Gln functions similarly in Gαq and in all other Gα-subunits to position a
catalytic water for nucleophilic attack on the γ-phosphate of GTP. Thus, Asn260 of PLC-β3
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interacts with Gln209 in Gαq to fix its position, and consequently, the rate of GTP
hydrolysis is dramatically increased. Other interactions in this region of PLC-β also appear
to be important for promotion of GTP hydrolysis. For example, Asn260 interacts with
Glu212 in Gαq, which also stabilizes switch 1 for GTP hydrolysis.
Results from biochemical analyses with purified proteins supported the model for the
mechanism of PLC-β-dependent inactivation of its activating G protein derived from the
Gαq/PLC-β3 structure.20 Phospholipid vesicles reconstituted with purified P2Y1 receptor
and heterotrimeric Gq were utilized to quantify steady-state GTP hydrolysis. Mutation of
Asn260 greatly decreased the maximal effect, but not apparent potency, of PLC-β3 for
stimulation of GTP hydrolysis. Amutant of PLC-β3 that lacked the EF-hand 3/4 loop
cassette almost completely lost GAP activity. Similarly, whereas agonist-stimulated
phospholipase activity of wild-type PLC-β3 rapidly turned off after addition of a P2Y1
receptor antagonist, the EF-hand mutants of PLC-β3 remained active in the presence of
antagonist. Thus, mutants of PLC-β3 deficient in capacity to stimulate GTP hydrolysis by
their activating G protein remained active following termination of receptor-promoted
exchange of guanine nucleotides on Gαq.
The role of the EF-hand region of PLC-β also was tested in vivo. Phototransduction in
Drosophila melanogaster involves rhodopsin promoted activation of a Gq/PLC-β signaling
complex.94 There-fore, transgenic flies were generated in which the endogenous PLC-β,
NorpA, that mediates the light response was replaced with NorpA harboring a mutation of
the relevant asparagine (Asn262) to alanine.20 Dark-adapted eyes were exposed to a 5 s
flash of orange light, and retinograms were generated. Eyes with wild-type NorpA or with
NorpA(N262A) exhibited similar amplitudes of the photoresponse to light. However, the
rate of termination of the photoresponse after cessation of light was decreased by greater
than 20-fold in NorpA(N262A) animals. Thus, the properties of reduced GAP activity in EF-
hand 3/4 loop mutants observed with purified proteins are recapitulated in a physiological
system.
Members of a large family of regulators of G protein signaling (RGS) proteins selectively
interact with Gα-subunits to markedly stimulate their rates of GTP hydrolysis.85,95,96 The
magnitude of the effect (>1000-fold stimulation of GTP hydrolysis) of RGS proteins is
similar to that observed for the effect of PLC-β on Gαq.90 The RGS proteins not only
function to promote rapid turnoff and/or inhibition of signaling mediated by most Gα-
subunits, but also serve to both sharpen and spatially focus GPCR-promoted signal
transduction.97 The mechanism where-by RGS proteins act as GAPs for Gα-subunits is
identical to the mode of regulation that independently evolved in PLC isozymes. Thus, the
interaction of Asn260 of PLC-β3 with Glu209 in Gαq is recapitulated by a functionally
equivalent interaction of an Asn in the structures of, for example, RGS4/Gαi298 and RGS9/
Gαt.92 Although the structure of an RGS protein in a complex with Gαq is not yet available,
the RGS protein-interacting surface of other Gα-subunits overlaps with a portion of the
PLC-β- interacting surface of Gαq.20
Phototransduction in mammals is mediated by Gαt-mediated activation of a cyclic GMP
phosphodiesterase, and normal recovery of the photoresponse requires RGS9-mediated
acceleration of GTP hydrolysis by Gαt.99,100 Although cyclic GMP phosphodiesterase is not
aGAP, it allosterically promotes an increase in binding of RGS9 to Gαt and therein
promotes its inactivation.92,101 The binding of phosphodiesterase in the effector pocket of
Gαt occurs analogously to the binding of PLC-β within the effector pocket of Gαq. The
capacity of PLC-β to be activated by Gαq and then function to turn off its activating
Gprotein evolved as coordinating actions of two different surfaces of the PLC-β effector
protein. In contrast, the high signal amplification of the photoresponse in mammals evolved
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in the activities of separate effectors and GAP proteins, which nonetheless interact
allosterically to promote a high level of signal-to-noise ratio in phototransduction.
PLC-β is not the only direct effector of Gαq since members of the Trio family of guanine
nucleotide exchange factors for Rho, i.e., Trio, Kalirin, and p63RhoGEF,102–104 and G
protein receptor kinase 2 (GRK2) bind to activated Gαq with high affinity.105,106 Thus,
biological effects downstream of the Gq-coupled GPCR also include Rho-mediated
responses, e.g., smooth muscle contraction, cell migration, and cell proliferation, and
desensitization of Gq-promoted signaling responses is regulated by direct interaction of the
activated Gα-subunit with GRK2, which targets the GPCR for phosphorylation. Comparison
of the structure of an activated complex of Gαq/p63RhoGEF104 with the structure of Gαq/
PLC-β320 reveals that these diverse effector proteins independently evolved a Gαq-binding
interface mediated by essentially identical residues in the two effector proteins. GRK2 also
interacts with Gαq in a similar fashion.106
In summary, dynamic regulation of Gαq/PLC-β signaling complexes underpins the capacity
of these signaling nodes to exhibit rapid activation and inactivation kinetics while
maintaining high levels of response amplitude, signal-to-noise ratio, and spatial focusing.
Importantly, precise interplay of two surfaces evolved in PLC-β isozymes to mediate this
regulation through a PLC-β-mediated process that has been coined “catch and release”.20
This term followed from the concept of “fly-casting” in which conformationally flexible
proteins sample a large space and then couple folding and binding in a mechanism that
increases the rate of formation of a protein— protein complex.107,108 Thus, the helix—turn
—helix region in PLC-β “catches” the effector region of GTP-bound Gαq (Figure 5A). The
EF-hand 3/4 loop region then engages the switch regions of the activated G protein and
stabilizes the transition state for GTP hydrolysis (Figure 4). “Release” then occurs with GTP
hydrolysis, which changes the conformation of switch 2 of Gαq and therein markedly
reduces its binding affinity for the helix—turn—helix region of PLC-β. The unbound lipase
is then free to sample the activation state of the GPCR-regulated G protein once more. As
discussed above, a helix—turn—helix in p63RhoGEF binds in the effector pocket of
activated Gαq in an analogous manner. p63RhoGEF is not aGAP and does not bind to the
surface of Gαq utilized by RGS proteins or the EF-hand 3/4 region of PLC-β. Thus, RGS
proteins can bind to activated Gαq in a complex with p63RhoGEF, and negative allosteric
regulation occurs between RGS2 binding and p63RhoGEF binding in this ternary complex
of RGS2, Gαq, and p63RhoGEF.109
The kinetics and mechanism of activation of PLC-β isozymes by Gβγ are much less well-
defined than is the case for Gαq-mediated activation. Clearly, the “kinetic scaffolding”
effect contributed by the Gαq-directed GAP activity of PLC-β is not operative during
activation by Gβγ, and the same holds true during activation of PLC-β2 by Rac. Whereas
the GAP activity of PLC-β against Gαq ensures that Gαq-activated PLC-β isozymes turn
off on a millisecond time scale when the activating GPCR is no longer agonist-bound, the
rate of turnoff of Gβγ- and Racactivated complexes must be much slower. Gβγ and Rac
have been reported to activate PLC-β2 at least in an additive fashion,25 but the interplay of
these two activators in PLC-β-mediated signaling has not been extensively studied.
Interestingly, PLC-β2 and PLC-β3 can be simultaneously activated by Gαq and Gβγ, and
studies with purified proteins illustrate that the combined presence of activated Gαq and
Gβγ results in supra-additive stimulation of PLC-β3.110 This cooperative activation
apparently accounts for synergistic activation of PLC-β often observed in cells during
simultaneous activation of Gq- and Gi-activating GPCR.111
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6. MECHANISM OF Gαq-MEDIATED ACTIVATION OF PLC-β ISOZYMES
PtdIns(4,5)P2 is membrane-bound, and the PLC isozymes are generally considered to be
soluble proteins. Early models for receptor-promoted activation of PLC included the concept
of recruitment to the plasma membrane. However, the mechanism- (s) of activation of these
signaling proteins is clearly more complex than simple membrane association, and this is
assuredly the case for PLC-β isozymes which are largely found at the plasma membrane
under basal conditions. Simple presence at the membrane is not optimal for efficient enzyme
activity since the binding pocket of the active site must be appropriately positioned to face
PtdIns(4,5)P2 at the membrane surface. Thus, Gαq-dependent activation includes orientation
of the lipase active site for substrate binding. Although bound Gαq also could propagate a
conformational change to the active site, this does not appear to be the case on the basis of
recent structures of PLC-β2 alone,93 PLC-β2 in an activated complex with Rac1,24 and
PLC-β3 in an activated complex with Gαq.20 Indeed, the primary mechanism of activation
of PLC-β by Gαq, and indeed the means whereby activation of most if not all PLC isozymes
occurs, is through removal of autoinhibition mediated by the X/Y-linker region of these
signaling proteins. We review the evidence for such a model below.
A broad range of studies over the past two decades illustrate that disruption of the X/Y-
linker of PLC isozymes increases enzymatic activity. For example, limited proteolysis of
PLC-δ,112 PLC-β,113 PLC-γ,114 and PLC-ζ115 isozymes resulted in higher basal activity.
Functional lipase activity also was reassembled from independent expression of the X and Y
domains of PLC-β 2116 or PLC-γ1,117 and the basal activities observed with these
recombinant proteins lacking X/Y-linkers exceeded that observed with expression of the
holoenzymes.
The X/Y-linker region in the first three-dimensional structure of a PLC isozyme, PLC-δ1,
was completely disordered.22 The more recent structures of PLC-β2 alone93 and PLC-β2 in
an activated complex with GTP-bound Rac124 revealed a slightly different situation. That is,
no electron density was associated with most of the X/Y-linker in these basal and activated
forms of PLC-β2, but importantly, a region (22 of the 70 residues) of the X/Y-linker was
ordered and occluded the active site (Figure 5B). Fourteen of these residues form an α-helix
that runs perpendicular to the TIM barrel, and the last eight residues are positioned on the
surface of the catalytic cleft and form a small 310 helix that makes direct hydrogen-bond-
mediated contacts with active site residues. These interactions within the active site occur in
structures of both the basal and Rac-bound forms of PLC-β2.93 Importantly, the structure of
PLC-β3 in complex with activated Gαq also displayed similar residues making direct
contacts with the active site.20 Occurrence of X/Y-linker-mediated occlusion of the active
site of PLC-β2 and PLC-β3 in structures of the G protein-bound enzymes indicates that
binding of activators is insufficient to remove autoinhibition. Indeed, super-position of the
three structures of PLC-β isozymes illustrates that no conformational changes occur within
the catalytic TIM barrel.20,24,93
Observation of direct occlusion of the active site of PLC-β2 by residues in the X/Y-linker
led Hicks and her co-workers93 to carry out a systematic deletion/mutation analysis of this
region. Removal of the stretch of 22 occluding residues resulted in a PLC-β2 isozyme with
remarkably higher basal activity when assessed by transient expression or as a purified
protein. Removal of all of the disordered portion or all of the X/Y-linker resulted in PLC-β2
mutants with even higher basal activity. Disruption of the active-site-interacting small 310
helix by introduction of a proline in place of a glycine, i.e., PLC-β2(G530P), also resulted in
a marked increase in enzyme activity. These data support the idea that basal activity of PLC-
β isozymes is strongly controlled by an autoinhibitory mechanism. G protein activators do
not directly interact with the X/Y-linker region (Figure 5B), and therefore, binding is not
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affected by its removal. Indeed, Gαq, Gβγ, and Rac all still activate PLC-β2 lacking the
linker,93 apparently because G protein binding still optimally orients the active site of the X/
Y-linker-deleted isozyme at the membrane surface.
Occurrence of X/Y-linker-mediated inhibition is not restricted to the PLC-β isozymes. Thus,
systematic deletion of the X/Ylinker markedly enhances the lipase activity of PLC-δ1, -ε, -
γ1, and -γ2 both in intact cells and with purified proteins.20,35,93 Removal of the X/Y-linker
also robustly activates PLC-ε, and this linker-deleted isozyme retains the capacity to be
activated by its upstream regulators RhoA and H-Ras.118
Although biochemical and structural studies highlight a common inhibitory role of the X/Y-
linker in all PLC isozymes, how is this function mediated by the very divergent primary
sequences of the various X/Y-linkers and how is this autoinhibition removed by Gαq
binding or by other activators? The most parsimonious model for activation of these lipases
involves an interfacial mechanism driven by electrostatic repulsions between the negatively
charged X/Y-linker and negatively charged membrane surfaces. Thus, activators do not
induce general conformational changes, but rather anchor and optimally orient PLC
isoforms at the plasma membrane to facilitate electrostatic repulsion and removal of the X/
Y-linker from the active site (Figure 5B). Consistent with this model, removal of
monovalent acidic phospholipids from the monolayer decreased by 3-fold the initial rate of
PtdIns(4,5)P2 hydrolysis by PLC-β1 and -δ1.119 Rac-mediated activation of PLC-β2 also
was abolished in detergent- mixed micelles, but not in phospholipid vesicles, which is also
consistent with the idea that recruitment to a membrane surface is critical for mediation of
interfacial activation.93 Finally, PLC-δ does not bind Gαq and is not activated by guanine
nucleotides.20 However, a chimeric recombinant form of PLC- δ1 that incorporates the
Gαq-binding helix—turn—helix region from PLC-β3 is sufficient to engender GPCR- and
Gαq-dependent lipase activation. Although additional mechanisms may support removal of
X/Y-linker-mediated autoinhibition, results to date favor the idea that activation largely
occurs through a membrane-surface-mediated mechanism.
The X/Y-linker region of PLC-γ isozymes differs dramatically from that of other PLC
isozymes since it contains a split PH domain, two SH2 domains, and an SH3 domain.9,11 X/
Y-linker-mediated autoinhibition of basal enzyme activity also occurs with these isozymes,
and recent studies implicate the C-terminal SH2 domain (cSH2) in mediating this effect.
Recruitment of PLC-γ isozymes to the plasma membrane occurs through engagement of the
N-terminal SH2 domain by activated receptor or nonreceptor tyrosine kinases. These kinases
in turn promote phosphorylation of a tyrosine in the intervening sequence between the cSH2
domain and SH3 domain which then interacts with the cSH2 domain to relieve
autoinhibition.35
7. CONCLUSIONS
A panoply of extracellular stimuli activate several hundred different GPCRs that are known
to activate Gq/PLC-β signaling complexes to promote inositol lipid signaling cascades.
These signaling responses of course include the classical mobilization of Ca2+ and activation
of protein kinase C that are cornerstones of PLC-dependent signaling, but the activities of a
broad range of membrane, cytoskeletal, and cytosolic proteins also are directly regulated by
PLC-mediated changes in membrane concentrations of PtdIns(4,5)P2. Thus, signaling
responses exhibiting many different characteristics radiate from PLC-β isozymes. The forms
that these signaling nodes take both spatially and functionally remain poorly understood, but
application of increasingly sophisticated live cell-imaging capabilities offers great promise
for new understanding. Strong insight into the physiological functions that depend on Gq/
PLC-β signaling complexes is available, but much is yet to be learned about their roles in
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human physiology and pathophysiology. Understanding of these nodes at the mechanistic
level has increased recently with the availability of three-dimensional structures of G
protein-bound PLC-β isozymes. This information should in turn provide both reagents and
new research directions that increase insight into inositol lipid signaling at the cellular and
intact animal levels. The absence of pharmacological agents that selectively target PLC
isozymes has definitely slowed research progress, and an out-standing contribution would be
made by discovery of such molecules. PLC-β-selective inhibitors may also have clinical
value. For example, a large preponderance of uveal melanomas have somatic mutations in
Gαq or Gα11 that result in constitutive activation of these signaling proteins and their
downstream signaling responses.120,121
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Conserved domain structure of the mammalian PLC isozymes. The 13 functional human
PLC isozymes were aligned on the basis of the conservation of the protein sequence, and a
dendrogram was constructed to cluster similar sequences into shared branches. The common
core of the PLC isozymes includes a PH domain (purple), a series of four EF-hands
(yellow), a catalytic TIM barrel (cadmium), and a C2 domain (blue). The four PLC-β
isozymes contain a long C-terminal (CT) domain (pink). The two PLC-γ isozymes include
conserved domains within the TIM barrel consisting of a split PH domain, two SH2
domains, and a single SH3 domain. PLC-ε contains a guanine nucleotide exchange domain
(RasGEF) that activates Rap1 and possibly other GTPases and two C-terminal RA domains
that bind activated Ras GTPases. A cysteine-rich (C) domain of unknown function occurs at
the N-terminus. PLC-ζ is the only mammalian PLC that lacks a PH domain. PLC-η
isozymes contain a serine/proline-rich (S/P) region in the C-terminus. Two PLC-like
proteins, L1 and L2, are also depicted due to their sequence homology to active PLCs. These
proteins have been reported to lack catalytic activity due to the absence of critical residues in
the active site. The structures of the substrate of PLC, PtdIns(4,5)P2, and its second
messenger products, Ins(1,4,5)P3 and DAG, are also depicted. PtdIns(4,5)P2 acts as a
signaling molecule by binding to a broad range of membrane, cytoskeletal, and cytosolic
proteins to change their activities, (Ins(1,4,5)P3) mobilizes intracellular Ca2+, and DAG
activates protein kinase C isozymes.
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Three-dimensional structure of PLC-β3 in an activated complex with Gαq. A ribbon
diagram is illustrated of the three dimensional structure (Protein Data Bank accession code
3OHM) of PLC-β3 in an activated complex with Gαq solved at 2.7 Å resolution by Waldo
and co-workers.20 The PH domain (light purple), EF-hands (yellow), TIM barrel (cadmium),
and C2 domain (blue) are colored as in Figure 1. The X/Y-linker region, which occludes the
active site of the lipase, is depicted in red, and the Ca2+ cofactor (yellow sphere) of the
active site is also shown. The approximate membrane-binding surface is across the top of the
figure. Gαq is illustrated in green except for the switch regions (Sw1, Sw2, and Sw3), which
are shown in red. GDP bound in the GTP-binding pocket is illustrated as a stick figure.
AlF4, which mimics the γ-phosphate of GTP and promotes the transition state, is shown as a
gray stick figure, and the Mg2+ cofactor (orange sphere) and catalytic H2O (red sphere) of
the nucleotide-binding site are also shown. The helix—turn—helix region (in blue and
labeled Hα1 and Hα2) at the end of the C2 domain interacts with Gαq in an effector-
binding pocket approximately between α3 and switch 2 of the activated G protein, and a
loop (yellow) between EF-hand 3 and EF-hand 4 of PLC-β3 interacts with the GTP-binding
region of Gαq to promote GTP hydrolysis.
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Kinetic model of GPCR-promoted Gαq-dependent activation of PLC-β. Agonists (A)
interact reversibly with GPCRs (R) to promote coupling to GDP-bound heterotrimeric Gq
(G) and consequential dissociation of GDP and binding of GTP to Gαq. GTP—Gαq then
binds with high affinity to PLC-β to activate the lipase and promote a high rate of
conversion of PtdIns(4,5)P2 (PIP2) to Ins(1,4,5)P3 (IP3) and diacylglycerol. Bound PLC-β
markedly enhances the rate of GTP hydrolysis by Gαq, resulting in a return of the G protein
to the inactive GDP-bound state and dissociation of PLC-β. In the continued presence of
agonist, activated R stays bound to Gq through multiple cycles of GTP binding and
hydrolysis since the rate of dissociation of R from GTP-bound Gαq is much slower than that
of the PLC-β- promoted return of the G protein to the GDP-bound state. This phenomenon
whereby agonist-activated R is retained in a signaling complex with the G protein through
multiple cycles of GTP binding and hydrolysis has been referred to by Ross,96, Neubig and
co-workers, 122 and others as a “kinetic scaffold”.
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Key interfaces in Gαq-promoted activation of PLC-β and PLC-β-promoted hydrolysis of
GTP by Gαq. Essentially the same orientation of the Gαq/PLC-β3 structure21 used in
Figure 2 is shown as a surface map using the same colors as in Figure 2 to depict the various
regions in PLC-β3 and Gαq. “Magnified” representations are utilized to show the key
interactions responsible for Gαq binding (effector site), for autoinhibition of the lipase (PLC
active site), and for PLC-β-mediated promotion of GTP hydrolysis by Gαq (Gαq active
site). The effector site magnification highlights the interaction of the helix—turn—helix
region of PLC-β3 with switch regions of activated Gαq. The PLC active site magnification
highlights the occlusion of the active site of the lipase by the X/Y-linker region (red) of the
PLC. The Gαq active site magnification highlights the interaction of the side chain nitrogen
of Asn260 of the EF-hand 3/4 loop of PLC-β3 with the side chain carbonyl of Gln209 of the
GTP-binding region of Gαq. The catalytic H2O (red sphere) orients the views of the
effector-binding site and GTP-binding region of Gαq, and the Ca2+ cofactor (yellow sphere)
orients the view of the PLC active site.
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Binding of G proteins to PLC-β isozymes. (A) The helix—turn—helix region of PLC-β3 is
shown engaging activated Gαq. (B) Membrane-anchored orientations are compared for
PLC-β3 bound to activated Gαq (Protein Data Bank accession code 3OHM)21 and PLC-β2
bound to activated Rac1 (Protein Date Bank accession code 2FJU).25 The palmitoylated N-
terminus of Gαq and geranylgeranylated C-terminus of Rac1 are modeled as sites of
membrane attachment of the G proteins. The X/Y-linker, which occludes the active lipase
site in both structures, is indicated in red, and the catalytic Ca2+ (yellow ball) present in the
active site of both structures is also shown. The figure highlights the dramatic difference in
PLC binding of the two activated G proteins: the switch regions (red) of activated Gαq
(green) primarily engage PLC-β3 through the helix—turn—helix region at the C-terminal
end of the C2 domain, whereas the switch regions (red) of activated Rac1 (green) engage
PLC-β2 entirely through interactions with the PH domain. The structures also illustrate that
activated Gproteins bind at great distance from the active site of the lipase. Activation in
both cases involves an interfacial mechanism whereby the occluding X/Y-linker, which is
highly negatively charged, is removed upon encountering the negative charge of the
membrane surface.
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